Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

Video

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

BTK inhibitors have revolutionized the treatment landscape of MCL, but the data show that approximately half of patients will not have a durable response. Ultimately, every patient will end up relapsing at some point, says McCulloch. The field is reaching the stage where the majority of patients have been exposed to a BTK inhibitor and are at the point of relapse. The question now is what to do next.

Early data have shown that it is a very difficult point in the treatment algorithm and there have been no satisfactory treatments that have surfaced, says McCulloch. The average response rate is typically about 30%. Moreover, the progression-free survival, in the best study, which was with venetoclax (Venclexta), is only about 3 months. This reflects a large unmet need, which investigators are hoping to fill with novel regimens.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,